Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St Peter׳s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.

✍ Scribed by Abd-Alazeez, Mohamed; Ahmed, Hashim U.; Arya, Manit; Allen, Clare; Dikaios, Nikolaos; Freeman, Alex; Emberton, Mark; Kirkham, Alex

• Book ID: 126960674
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 415 KB
• Volume: 32
• Category: Article
• ISSN: 1078-1439
• DOI: 10.1016/j.urolonc.2014.01.008